JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by HUDAK, W. J.
Right arrow Articles by KUHN, W. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HUDAK, W. J.
Right arrow Articles by KUHN, W. L.
Journal of Pharmacology And Experimental Therapeutics, Vol. 173, Issue 2, 371-382, 1970
Copyright © 1970 by American Society for Pharmacology and Experimental Therapeutics

CARDIOVASCULAR PHARMACOLOGY OF PERHEXILINE

W. J. HUDAK 1, R. E. LEWIS 1, and W. L. KUHN 1

1 Department of Pharmacology, The Wm. S. Merrell Company, Division of Richardson-Merrell Inc., Cincinnati, Ohio

A new cardiovascular drug, perhexiline—(2(2,2-dicyclohexylethyl)piperidine) hydrochloride, was studied in animal experiments. It produced vasodilatation in the systemic and coronary vascular beds in open-chest dogs. In contrast to nitroglycerin, it increased coronary blood flow which was maintained in the presence of decreased blood pressure and resistance in the systemic circulation. In the closed-chest dog, it produced marked increases in both coronary and femoral blood flows with corresponding decreases in resistances, decreased mean arterial blood pressure and slightly increased cardiac output and heart rate. Myocardial contractile force was slightly reduced. The coronary vasodilatation produced by this compound is not mediated by either the beta receptors or inhibition of adenosine deaminase activity, but is due to a direct effect on vascular smooth muscle. In intact anesthetized dogs, this compound produced hypotension which was accompanied by a decrease in heart rate. The decrease in blood pressure is due to a direct action of perhexiline on vascular smooth muscle. The decrease in heart rate is not mediated via the vagi or due to blockade of beta receptors, but is due to a direct cardiac membrane effect.

Submitted on July 23, 1969
Accepted on March 1, 1970




This article has been cited by other articles:


Home page
 CirculationHome page
L. Lee, R. Campbell, M. Scheuermann-Freestone, R. Taylor, P. Gunaruwan, L. Williams, H. Ashrafian, J. Horowitz, A. G. Fraser, K. Clarke, et al.
Metabolic Modulation With Perhexiline in Chronic Heart Failure: A Randomized, Controlled Trial of Short-Term Use of a Novel Treatment
Circulation, November 22, 2005; 112(21): 3280 - 3288.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1970 by the American Society for Pharmacology and Experimental Therapeutics.